Clinical efficacy of eprosartan.
Eprosartan is a new, structurally distinct, nonbiphenyl, nontetrazole, nonpeptide, orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor. In placebo-controlled trials, it led to a dose-related antihypertensive response, clinically significant reductions in blood pressure and full 24-hour blood pressure control with once/day administration of 600 mg. Eprosartan provides clinically significant reductions in blood pressure in patients with mild to severe hypertension regardless of age, gender, and race. The antihypertensive effect of eprosartan is comparable with those of other antihypertensive agents. Whereas a relationship exists between dosage and antihypertensive effect, there is no such relationship between dosage and adverse events, the frequency of which is comparable with that with placebo.
Weber
M
M
Department of Medicine, Brookdale University Hospital, Brooklyn, New York 11212, USA.
D000179:Acrylates / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013876:Thiophenes
D000179:Acrylates; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan